ARK Innovation ETF (ARKK) Stock Price Today
Aura AI Summary
Key Stats
- $7.92BMarket Cap
- 3,264,054Volume
- -Sector
- $92.7852W High
- $63.5252W Low
- 113 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 0% Sell | 100% BuyTrading Activity
Track ARK Innovation ETF (ARKK) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, ARK Innovation ETF has traded between a low of $63.52 and a high of $92.78, highlighting its annual price range. Buy and sell ARK Innovation ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Most Recent News
Volvo to cut 2,500 jobs after Q3 loss due to weak China, US markets
Volvo Cars announced plans to cut 2,500 jobs following a sharp decline in earnings for the third quarter. The company reported an operating loss of 5.6 billion Swedish Kronor ($563.7 million), a significant drop from a 6.4 billion Kronor profit in th...

Steriwave cuts surgical-site infections by 51.5% at Canada's largest cardiac center, boosting patient safety.
Ondine Biomedical's Steriwave antimicrobial treatment reduced surgical-site infections by 51.5% at the University of Ottawa Heart Institute, Canada's largest cardiac center, dropping infection rates from 3.3% to 1.6% in 2,172 procedures. Patient comp...

Enozertinib shows strong results in first-line NSCLC with EGFR atypical mutations, advancing to global Phase 3 trial in 2027
ORIC Pharmaceuticals announced promising Phase 1b data for enozertinib in first-line NSCLC patients with EGFR atypical mutations, showing an 84% systemic response rate and 70% intracranial response rate despite high baseline brain metastases. The dru...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.